Author: Jane Griffin

SAN FRANCISCO–(BUSINESS WIRE)–Ossium Health, a clinical-stage biotechnology company pioneering off-the-shelf bone marrow therapies derived from deceased organ donors, today announced it will present new clinical data from its ongoing PRESERVE I study at the 2026 Tandem Meetings taking place on February 4-7, 2026 in Salt Lake City, UT.

Ossium will deliver one oral presentation and three poster presentations highlighting clinical experience with its cryopreserved, donor-derived bone marrow platform. The featured oral presentation will showcase first-in-human clinical data from the first four patients treated in the PRESERVE I study, marking an important milestone in the advancement of off-the-shelf bone marrow transplantation. Ossium’s Chief Medical Officer, Dr. Sagar Munjal, will present the study’s encouraging preliminary data, which demonstrate the safety and feasibility of transplanting bone marrow derived from deceased donors. Additional poster presentations underscore key advantages of Ossium’s off-the-shelf bone marrow platform, including its ability to provide immediate graft availability in urgent scenarios when a living donor becomes unavailable, as well as its potential to reduce relapse risk.

Oral Presentation

Title: A First-in-Human Study of HLA-Partially to Fully Matched Allogeneic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies
Presenter: Sagar Munjal, MD, Chief Medical Officer & Senior Vice President, Ossium Health
Presentation ID: 89
Date and Time: Saturday, Feb 7, 11:30 AM – 11:45 AM MST
Location: Ballroom J

Poster Presentations

Title: First Report of Successful, Lifesaving and Timely Graft Rescue Using an Off-the-Shelf Cryopreserved, Cadaveric Marrow in Myeloablative Transplant Following the Unexpected Unavailability of a Living Matched Unrelated Donor
Poster ID: 160
Date and Time: Thursday, Feb 5, 6:30 PM – 8:00 PM MST
Location: Hall AB

Title: High-Dose Cryopreserved Bone Marrow from Deceased Donors May Reduce Relapse in HLA-Mismatched Allogeneic Transplantation: Day 180 Post-Transplant HOPE Update
Poster ID: 280
Date and Time: Thursday, Feb 5, 6:30 PM – 8:00 PM MST
Location: Hall AB

Title: Demonstrating the Feasibility of Refreezing Previously Cryopreserved Bone Marrow Following Reprocessing
Poster ID: 296
Date and Time: Thursday, Feb 5, 6:30 PM – 8:00 PM MST
Location: Hall AB

“These presentations highlight the growing clinical body of evidence supporting the feasibility, safety, and transformative potential of Ossium bone marrow,” said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. “We look forward to sharing insights from PRESERVE I and related clinical experience with the transplant community at Tandem.”

The company will also exhibit at Booth #106, where attendees can learn more about Ossium’s organ donor-derived bone marrow banking platform and clinical studies.

The Tandem Meetings are jointly hosted by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) and represent one of the premier global forums for advances in hematopoietic cell transplantation and cellular therapy.

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority, under Contract No. 75A50124C00032.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com.

Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth.

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]

SAN FRANCISCO–(BUSINESS WIRE)–A new peer-reviewed study published in Cytotherapy, the official journal of the International Society for Cell & Gene Therapy (ISCT), reports early clinical experience using Ossium Health’s organ donor-derived, cryopreserved bone marrow as an off-the-shelf graft source for allogeneic hematopoietic cell transplantation (alloHCT). The study provides the most comprehensive description to date of a fully centralized, GMP-manufactured bone marrow cryopreservation platform, demonstrating that off-the-shelf marrow can be produced at scale with exceptional consistency, long-term stability, and strong clinical performance.

For decades, allogeneic transplantation has relied on fresh grafts from living donors, accepting significant logistical risk, donor attrition, and delays that prevent many patients from ever reaching transplant. Ossium’s approach fundamentally changes that paradigm by offering a high-quality, banked graft source that can be delivered within days rather than months.

The published data highlight Ossium’s extensive cryopreservation validation. By applying novel methods along with manufacturing discipline—rather than center-specific, operator-dependent procedures—Ossium eliminates the variability that has historically plagued cryopreserved allogeneic grafts.

“The COVID-19 pandemic made it clear that cryopreservation is essential, but it also exposed how variable outcomes can be when it’s done inconsistently,” said Erik Woods, PhD, Chief Science Officer, Co-Founder, and EVP of Ossium Health. “What we’ve demonstrated here is that when cryopreservation is engineered, validated, and controlled in a true manufacturing process, you can deliver consistently high-quality bone marrow that performs clinically.”

In the study’s reported clinical experience, three high-risk patients with acute myeloid leukemia (AML) received cryopreserved bone marrow from Ossium through an expanded access program. All patients achieved rapid neutrophil and platelet engraftment, full donor chimerism, and successful immune reconstitution, with no infusion-related toxicity, cytokine release syndrome, or DMSO-related adverse events.

“These results reinforce that Ossium’s cryopreserved marrow is not only logistically superior—it’s biologically potent,” Woods added. “Patients were able to proceed to transplant when they needed it, not when donor logistics allowed, and there were no trade-offs in treatment outcomes.”

By demonstrating that cryopreserved bone marrow can be standardized, stable, and clinically effective, the study challenges the long-held assumption that fresh grafts are inherently superior for alloHCT. Ossium’s platform decouples transplantation from donor scheduling, transportation delays, and attrition—opening the door to faster, more predictable access to life-saving therapy and establishing a new infrastructure model for the field.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com.

Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth.

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]

SAN FRANCISCO–(BUSINESS WIRE)–Ossium Health, a bioengineering company that developed a first-of-its-kind bank of bone marrow available on-demand, will present new clinical data at the at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held December 6-9, 2025 in Orlando, Florida.

Ossium’s key abstract includes clinical data from four patients with hematologic malignancies that were treated with hematopoietic stem cells derived from the vertebral bodies of deceased organ donors. All four patients achieved rapid neutrophil engraftment, platelet recovery, and full donor chimerism. All cases of acute GVHD were successfully managed with steroids and no chronic GVHD was reported. By Day 180, all evaluatable patients were alive and relapse-free. These early results indicate that Ossium’s deceased-donor-derived bone marrow is a promising new graft source that supports robust engraftment while addressing both relapse and GVHD prevention.

The abstract is now available online:

High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update
Abstract Number: 5976
Presenter: Sagar Munjal, MD, MS (Chief Medical Officer, Ossium Health)
Date/Time: Monday, December 8, 06:00 PM – 08:00 PM EST
Poster Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III

Ossium’s presence at ASH 2025 underscores the company’s commitment to improving access, speed, and quality in hematopoietic cell transplantation. By presenting new clinical and scientific data and engaging directly with leaders in the hematology community, the company aims to raise awareness to how organ donor bone marrow is driving meaningful therapeutic advantages and overcoming longstanding donor availability limitations.

“We’re excited to share our latest clinical insights with the hematology community at ASH,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “Our findings demonstrate the potential of organ donor bone marrow to transform patient outcomes, and we look forward to engaging with clinicians and researchers at our booth.”

In addition to its presentation, Ossium Health will host an exhibit at Booth 112, where attendees can learn more about the company’s organ donor-derived bone marrow and its clinical programs.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com.

Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth.

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]

SAN FRANCISCO–(BUSINESS WIRE)–Ossium Health, a bioengineering company dedicated to improving human health through its organ donor bone marrow banking platform, announced today that Dr. Susannah Cantrell, PhD, has joined its leadership team as Chief Commercial Officer (CCO).

In her new role, Dr. Cantrell will be responsible for leading Ossium’s commercial strategy, go-to-market planning, and partnerships as the company scales its unique platform to meet the needs of the bone marrow transplant field. She will play a critical role in driving the company’s platform from development into full-scale commercial availability.

“Susannah brings a rare combination of commercial leadership, scientific rigor, and operational excellence — exactly what Ossium needs as we advance our platform,” said Kevin Caldwell, Co-Founder & CEO of Ossium Health. “Her track record of building high-performing commercial teams, especially in complex, regulated environments, will be invaluable as we expand adoption of our organ donor bone marrow.”

Dr. Cantrell brings more than two decades of experience in biotechnology and pharmaceuticals. Most recently, she served as Chief Business Officer at Brii Biosciences where she oversaw business development, alliance management, and commercial activities.

Prior to Brii Biosciences, Dr. Cantrell served as Chief Business Officer and Chief Operating Officer at Second Genome, where she oversaw the company’s operations, business development, finance, and facilities. Dr. Cantrell also served as Executive Vice President & Chief Commercial Officer at Tricida, where she built a U.S.-focused commercial organization from the ground up. She held senior leadership roles at Gilead Sciences, including Vice President, Global Commercial Strategy & Marketing – Oncology, where she played a key part in growing Gilead’s oncology and inflammation business lines. Earlier in her career, Dr. Cantrell held various global sales and marketing roles at Genentech/Roche and GlaxoSmithKline.

Dr. Cantrell holds a B.A. in Biology from Westminster College and a Ph.D. in Biochemistry from the University of Missouri-Columbia.

“I am thrilled to join Ossium Health at such an exciting time in its journey,” said Dr. Cantrell. “Their platform has the potential to fundamentally change how we think about cell therapy, and I look forward to working with the team to bring those innovations to patients.”

Her appointment marks a significant step in strengthening Ossium’s leadership as the company prepares for its next phase of growth, advancing commercial readiness and supporting the upcoming launch of its bone marrow at transplant centers nationwide.

About Ossium Health

Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health’s manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com.

Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth.

Contacts

Jane Griffin
Ossium Health, Inc.
415-513-5535
[email protected]